Between 1985 and 1999, as managed
|
|
- Madison Fox
- 5 years ago
- Views:
Transcription
1 National In Use Of Medications In Office- Based Practice, Drugs were discussed 59 percent more often in office visits in 1999 than in 1985, rising to a rate of 146 prescriptions per 100 visits. by Catharine W. Burt ABSTRACT: Increases in physician office visits involving the use or prescribing of a drug were observed between 1985 and 1999 using data from the National Ambulatory Medical Care Survey. The prescription rate increased from 109 to 146 prescriptions per 100 visits. Growth in drug mention rates for specific therapeutic classes varied by patients age. The rate of multiple prescriptions per visit rose 39 percent. Similar-size increases were observed after differences in patients age, number of comorbidities, source of payment, and physician specialty were controlled for. Between 1985 and 1999, as managed care spread nationwide, more practice guidelines were developed for medication treatment. Changes in drug coverage, drug research and development (R&D), faster Food and Drug Administration (FDA) approval, and increased drug marketing to physicians and consumers are likely contributors to increased use of medications in ambulatory care. In this paper I use data from the National Ambulatory Medical Care Survey (NAMCS) to track physicians use of medications during this period. I describe trends in medication use at or after office visits, including patients and physicians characteristics that are related to increased reliance on medications. Methods Data in this study are from NAMCS, a multistage probability-based sample survey of 2,500 4,500 office-based physicians conducted by the National Center for Statistics (NCHS). NAMCS has collected patient encounter data periodically since 1973 and annually since For this report I performed a secondary analysis of survey data from 1985, , , , and Where possible, two years of data were combined to make the estimates more reliable. A total of 288,941 patient encounter records were used in this analysis. Details on the survey may be found elsewhere. 1 Physicians were asked to complete an encounter form for a sample of approximately thirty patient visits in a randomly assigned one-week reporting period during the survey year. Sample weights were applied to make national estimates of the number and characteristics of office visits. The response rates ranged from 80 percent in 1985 to 63 percent in Because NAMCS estimates are based on a sample of physician encounters, they are subject to sampling error. Standard errors were computed using SUDAAN, which takes the complex sample into consideration. 2 State- Catharine Burt is chief of the Ambulatory Care Statistics Branch at the National Center for Statistics, U.S. Centers for Disease Control and Prevention, in Atlanta. 206 July/August Project HOPE The People-to-People Foundation, Inc. Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
2 ments about significance are based on a weighted least-squares regression of estimates since The average relative standard error for the estimates presented here is.09. A multiple logistic regression analysis was performed using SUDAAN on the 1985 and 1999 data to model multiple prescribing events at office visits. The patient record form is used to collect data on patients characteristics such as age, sex, and race and on visit characteristics such as diagnosis, services provided, and medications prescribed. Physicians record all new or continued medications ordered, supplied, or administered at the visit, including prescription and nonprescription preparations, immunizations, desensitizing agents, and anesthetics. The maximum number of medications collected during the survey history varied from five to eight. This analysis used the first five drug mentions. Therapeutic class was assigned to the drug mentions based on the 1995 edition of the National Drug Code Directory (NDC). 3 In this analysis drugs classified in multiple categories are tabulated under the first category only. A report describing the method and instruments used to collect and process drug information has been published elsewhere. 4 I present unadjusted rates here because no significant differences appeared between drug mention rates that were ageadjusted and those that were not. Results The annual number of visits to office-based physicians increased 19 percent, from million in 1985 to million in The number of drug mentions during this time period increased 59 percent, from 693 million to 1.1 billion, with a resulting 34 percent increase in the drug mention rate from 109 to 146 drugs per 100 visits. The increase in drug mention rates was found for all age groups and all physician specialties except general surgeons, cardiologists, and dermatologists (Exhibit 1). The largest increase was found for psychiatrists, whose drug mention rate increased from 82 to 178 drugs per 100 visits. The distribution of visits to these specialties varied over time, as did some of the more common chronic diagnoses that are treated with medication therapy. The percentage of visits for hyperplipidemia and related lipoid disorders (such as high cholesterol and high triglycerides) had the largest increase (Exhibit 2). The number of medications at the selected chronic disease visits shown in the exhibit also increased. Increases were found for all of the major therapeutic classes, with the notable exception of antimicrobial agents, which declined 12 percent. The penicillins and tetracycline led the decline, and there was an increase in quinolones broad-spectrum antibiotics used to treat gastrointestinal, urinary tract, and lower respiratory tract infections. Six therapeutic classes account for 80 percent of the increase in the overall drug mention rate: central nervous system drugs, hormones, respiratory drugs, pain relief drugs, metabolics/nutrients, and cardiovascular-renal drugs (Exhibit 3). At a more detailed level, nine classes account for 75 percent of the observed increase (Exhibit 4). Increases in antidepressants alone account for 13.5 percent of the observed increase during the study period. Other classes contributing the most include lipid-lowering drugs and drugs to treat hypertension and diabetes. For comparability in this analysis, current therapeutic classes were assigned to 1985 drug mentions, because the 1995 NDC classification has more four-digit classes than there were in Drug mention increases varied by patient s age and therapeutic class (Exhibit 5). While the drug mention rate increased for almost all therapeutic classes for seniors, the largest increase was found for hematologic agents (187 percent, from 1.9 to 5.5 mentions per 100 visits). The largest increase observed for patients ages was 109 percent for metabolics (from 4.8 to 10.0 mentions), which includes lipid-lowering drugs such as Lipitor. Neurologic agents also showed a large increase among persons in this age group (from 1.6 to 2.6 mentions) and among those ages (from 2.4 to 4.7 mentions). Central nervous system drugs including selective serotonin reuptake inhibitors (SSRIs) had the largest in- HEALTH AFFAIRS ~ Volume 21, Number Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
3 EXHIBIT 1 Estimates Of Physician Office Visits And Drug Mentions, Selected Years Percent change since 1985 Number of visits (thousands) Visit rate per 100 persons Mean number of diagnoses Drug mentions (millions) 636, , , , , % a , , a 59 a Drug mentions per 100 visits All ages Under a 29 a 19 a 31 a 28 a 27 a Physician specialty General/family practice Internal medicine Pediatrics General surgery OB/GYN Orthopedic surgery Cardiovascular diseases Dermatology Urology Psychiatry Neurology Ophthalmology Otolaryngology All other a 25 a 19 a a 37 a a 116 a 36 a 78 a 39 a 33 a Percent of drug visits that have multiple medications 45.3% 45.2% 54.7% 54.5% 58.1% 28 a SOURCE: National Ambulatory Medical Care Survey, various years. NOTES: Drug mention rate is number of drug mentions divided by number of visits multiplied by 100. Estimates for , , and are annual averages. a Trend is significant (p <.01). crease for patients ages (130 percent, from 3.8 to 8.8 mentions). The therapeutic class with the largest increase for children was also central nervous system drugs, which increased 327 percent (from 1.1 to 4.5 mentions). Among the most frequently mentioned drugs in this class for children s visits in 1999 was Ritalin for treating attention deficit hyperactivity disorder (ADHD). The percentage of physician office visits with at least one medication mentioned increased by only 8 percent, from 61.2 to 66.2 percent of visits. This was driven by an increase for patients ages Multiple drug prescribing accounted for the largest part of the increase (Exhibit 6). Overall, the percentage of visits with two or more drugs increased 39 percent. A similar increase was found for each age group studied. A multiple logistic regression analysis modeled factors influencing multiple prescriptions among drug visits (for visits with any medications prescribed): patient s age, expected source of payment, number of diagnoses, and physician s specialty. Number of diagnoses at the visit measures comorbidity, which is related to the number of drugs prescribed. 5 Visits by persons with multiple conditions are more likely to require multiple medications. The percentage of visits with three diagnoses was 19.4 in 1999, up from 8.2 percent in Thus, some of the increase in drug prescribing 208 July/August 2002 Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
4 EXHIBIT 2 Percentage Of Physician Office Visits And Drug Mention Rates For Selected Chronic Conditions, 1985 And Diabetes (250) Drug mention rate Hyperlipidemia (272) Chronic respiratory (472, 473, 477) COPD ( ) Hypertensive disease ( ) Depression and related psychoses ( , 298.0, 298.1, 300.4) Percent of office visits for selected conditions NOTES: Drug mention rate is the number of drug mentions per 100 visits. ICD-9-CM codes are in parentheses and could be mentioned in any of three diagnoses collected. COPD is chronic obstructive pulmonary disease. EXHIBIT 3 Drug Mention Rates By Therapeutic Class, 1985 And 1999, With Change Since 1985 Number of drugs per 100 visits Therapeutic class Difference Percent distribution of differences All % 34% Central nervous system Hormones Respiratory Pain relief Metabolic/nutrients Cardiovascular/renal Ophthalmics Gastrointestinal agents Skin/mucous membranes Immunologics Neurologic agents Hematologic agents Antimicrobial agents Other classes Percent change since HEALTH AFFAIRS ~ Volume 21, Number Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
5 EXHIBIT 4 Top Detailed Therapeutic Classes Accounting For Most Of The Increase In Overall Drug Mention Rates At Physician Office Visits, 1985 And Antidepressants Hyperlipidemia drugs ACE inhibitors Antihistamines Calcium channel blockers Acid/peptic disorders Blood glucose regulators Vaccines Estrogens Number of mentions per 100 visits 6 7 NOTE: ACE is angiotensin converting enzyme. would be related to more visits in 1999 by patients with multiple diagnoses. Physician specialty was included in the model because of the large variation in drug therapies used in the diseases in which physicians specialize. The overall model explains 13 percent of the variation in multiple prescribing at drug visits. The odds that a drug visit had multiple drug mentions in 1999 over 1985 was 1.43 after adjusting for the all the factors in the model (95 percent confidence interval, 1.28, 1.61) (Exhibit 7). Discussion The NAMCS data examined here show increased use of medications since 1985 for all age groups, most specialties, and most therapeutic classes. The magnitude of the increases for specific therapeutic classes varied by age group. While one assumption is that increased medication use is due to aging of the population, differences in the proportions of middleage and senior patients during this time period account for only about 20 percent of the observed increase in overall drug mention rates. In 1985 patients age forty-five and older represented 42.1 percent of physician office visits. 6 In 1999 they represented 52.1 percent. 7 Adjusting the 1999 drug mention rate to the 1985 age distribution of office visits still leaves a 28 percent increase in drug mention rates. Another potential explanation is that doctors may be treating patients who, in general, have more comorbidities than in the past. The NAMCS data show that the relative proportion of visits with three diagnoses more than doubled during the study period. About half of the observed increase in drug mention rates can be explained by this change in case-mix. The percentage of visits with multiple drug mentions increased from 45.3 percent in 1985 to 58.1 percent in 1999, an overall increase of 28 percent. The logistic regression model shows that after differences in the distribution of visits by patients age, number of diagnoses, source of payment, and physician specialty are adjusted for, physicians were 43 percent more likely to prescribe multiple drugs in 1999 than in Examining other factors in the model also shows interesting evidence leading to multiple prescribing. Visits with government payment sources were more likely to receive multiple drugs (Medicare, odds ratio = 1.24; Medicaid, odds ratio = 1.44). Since these odds ratios are adjusted for differences in patients age and number of diagnoses, this may indicate that these patients are more likely to have con- 210 July/August 2002 Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
6 EXHIBIT 5 Drug Mentions Per 100 Visits, By Therapeutic Class And Patients Age, 1999, With Significant Percentage Changes Since 1985 Patients age (years) Therapeutic class Antimicrobial agents Cardiovascular/renal (87%) 6.5 (18%) Central nervous system Gastrointestinal agents 4.5 (327%) (130%) (74%) (64%) 8.0 (45%) 11.5 (27%) 10.3 (62%) Hematologic agents Hormones 0.3 a 3.0 (126%) 1.6 a (37%) 2.1 (75%) 20.7 (81%) 5.5 (187%) 21.0 (79%) Immunologics Metabolic/nutrients 25.4 (69%) 2.8 (73%) 4.5 (80%) (109%) 2.4 (58%) 17.2 (96%) Neurologic agents Ophthalmics (94%) (102%) (60%) 13.6 Pain relief Respiratory 8.0 (94%) 23.3 (39%) 9.8 (50%) 15.1 (81%) 16.9 (54%) 14.4 (73%) 17.9 (21%) 14.9 (62%) 19.0 (15%) 11.5 (41%) Skin/mucous membranes 9.3 (46%) (15%) 8.4 (50%) 7.4 (59%) NOTE: A lack of a percentage change indicates that there was not a significant linear trend since 1985 at the.01 level. a Estimate does not meet standard of reliability. EXHIBIT 6 Rise In Percentage Of Physician Office Visits With At Least One Drug Mention And Visits With Multiple Mentions, By Patients Age, At least 1 drug 2ormoredrugs Under 15 years years years years 65 years and older Percent change, HEALTH AFFAIRS ~ Volume 21, Number Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
7 EXHIBIT 7 Results From Multiple Logistic Regression In Modeling Multiple Drug Use In 1985 And 1999 For Visits At Which At Least One Drug Was Mentioned Visit characteristic Odds ratio 95% CI Age (ref = years) Under a a 65+ a Number of diagnoses (ref = 1) None 2 a 3 a Source of payment (ref = private insurance) Self-pay HMO Medicaid a Medicare a Other Physician specialty (ref = general/family practice) Internal medicine a Pediatrics General surgery a OB/GYN a Orthopedic surgery a Cardiovascular disease a Dermatology Urology a Psychiatry Neurology a Ophthalmology a Otolaryngology Other specialties a , , , , , , , , , , , , , , , , , , , , , , , , , 1.57 Year (ref = 1985) 1999 a , 1.61 NOTES: HMO is health maintenance organization. OB/GYN is obstetrics/gynecology. a Significant contributor to modeling whether a drug visit will have multiple drugs mentioned (p <.05) ditions that are amenable to drug treatment. The remainder of the observed increase could be driven by several factors, including the development of newly formulated drugs to treat chronic conditions, increased health insurance and prescription drug coverage, increased focus by physicians and health plans on managing health care, and direct-toconsumer marketing of drugs. New drugs. FDA approvals have doubled since the early 1980s, from an average of about nineteen per year to thirty-eight in the late 1990s. 8 Also, the length of time for approval of new drugs declined from about thirty-three months in 1986 to twelve months in This trend coincides with increased R&D by pharmaceutical companies. There were 104 new molecular entities (NMEs) approved between 1997 and 1999, many of which are used to treat chronic conditions. They accounted for 3.7 percent of all drug mentions in For example, among lipid-lowering 212 July/August 2002 Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
8 drugs, by 1989 statins replaced fibrates as the most heavily used medication. 10 Shifts from older statins to atorvastatin (Lipitor) also are associated with increased prescription patterns. Lipitor was first marketed in March Other frequently prescribed new drugs include Norvasc (first marketed in 1992), Claritin (1993), Zoloft (1992), Paxil (1993), Zocor (1992), Prempro (1995), and Glucophage (1995). These drugs were in the top twenty, by number of dispensed prescriptions in About half of the drugs mentioned in office visits in 1999 (and one-third of the drug mentions) were not mentioned in One of the main contributors to increases in drug prescribing are attributable to increased use of antidepressants, of which there have been at least eight new drugs since Drug coverage and managed care. Payment and delivery system issues may also be converging to influence the prescribing and use of medications. Payment sources for physician office visits have undergone huge changes since The NAMCS data show that in 1985, 35 percent of visits were paid for by the patient, in contrast to only 5 percent in The relative share of visits paid for by Medicare rose 40 percent and by private insurance or health maintenance organization (HMO), almost 200 percent. The percentage of insured workers having drug coverage rose from 91 percent in 1988 to 99 percent in As managed care made inroads into Medicare during the early 1990s, a higher proportion of seniors chose a plan option that provided some prescription drug benefit. To be competitive, many plans increased their drug coverage. More than half of all Medicare recipients now have some kind of drug coverage from supplemental plans. 14 Studies have shown that the likelihood of having drug coverage is directly related to the number of prescriptions a person needs. 15 The increased probability of filling a prescription may be related to physicians choice of medication over other therapies. The data from this study indicate that the drug mention rate increased at the same rate for all payment sources. If the 1999 visits were distributed like the 1985 visits with regard to source of payment, the same level of increase in total drug mention rate would have been observed. The effect of managed care on drug prescribing may be more subtle. Increased emphasis on managed care has also likely led to increased use of treatment guidelines, many of which included medical consensus on medication use. The proliferation of practice guidelines developed and supported by third-party payers would help to explain the increased reliance on medication therapy. For example, treatment guidelines for hypertension include multiple drug regimens in many cases. 16 Similarly, there has been an increased emphasis on medications for pain relief. 17 While approximately one-quarter of office visits include mention of the patient s pain, the relative percentage of those visits that included mention of a pain medication increased 21 percent, from 24 percent of visits in 1985 to 29 percent in 1999 (data not shown). The percentage of visits with no direct pain complaint that had a mention of pain medication increased from 6 percent to 9 percent during the study period (data not shown). DTC advertising. Direct-to-consumer (DTC) advertising for prescription drugs blossomed in 1997 after the FDA clarified rules pertaining to ads, making it easier to launch television, print, and radio ad campaigns. Such increased mass-media advertising has coincided with a sharp rise in the number of prescriptions written and overall spending on prescription drugs. Doctors wrote 34 percent more prescriptions in 1999 than in 1998 for the twenty-five DTC-promoted drugs that contributed most to overall drug spending, while they wrote only 5 percent more prescriptions for all other prescription drugs. 18 For example, Pfizer increased DTC advertising for Lipitor sixfold between 1998 and 1999 and saw prescriptions increase by 50 percent. Of course, pharmaceutical companies may have chosen to apply DTC advertising to the new drugs that were expected to have the most use. Nevertheless, as DTC advertising has increased over the years, so has the number of medications prescribed increased, whether DTC advertising motivates patients to come to the doctor or HEALTH AFFAIRS ~ Volume 21, Number Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
9 motivates doctors to prescribe more drugs at the patient s request. 19 The use of medications in treating medical conditions is likely to continue to rise as the baby-boom generation stretches from middle to old age. Scientific breakthroughs will find applications in better-engineered drugs to treat many other conditions. Better treatment of acute and chronic conditions is associated with increased life expectancy. However, this will lead to even greater dependence on such drugs for maintaining a high quality of life. Data from the Chain Pharmacy Industry Profile show that in drug spending rose by 165 percent with the most recent average yearly increase about 15 percent. 20 At that rate, drug spending will likely double in the next five years, despite patent expirations for many popular brand-name drugs. NOTES 1. See the annual summaries that are part of the Advance Data from Vital and Statistics publications, National Center for Statistics (NCHS), adata.htm (18 April 2002). 2. B.V. Shah et al., SUDAAN User s Manual, Release 7.0 (Research Triangle Park, N.C.: Research Triangle Institute, 1996). 3. U.S. Food and Drug Administration, National Drug Code Directory, 1995 ed. (Washington: Public Service, 1995). 4. H. Koch, The Collection and Processing of Drug Information: National Ambulatory Medical Care Survey, United States, 1980, Vital and Statistics, Series 2, no. 90, DHHS Pub. no. (PHS) (Washington: U.S. Government Printing Office, March 1982). 5. In 1999 the drug mention rate at visits with three diagnoses was mentions per 100 visits; at visits with only one diagnosis, the rate was mentions. Up to three diagnoses are collected at each visit in NAMCS and coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (Washington: PHS, 1999). 6. T. McLemore and J. DeLozier, 1985 Summary: National Ambulatory Medical Care Survey, Advance Data from Vital and Statistics, no. 128 (Hyattsville, Md.: National Center for Statistics, 2001). 7. D. Cherry, C. Burt, and D. Woodwell, National Ambulatory Medical Care Survey: 1999 Summary, Advance Data from Vital and Statistics, no. 322 (Hyattsville, Md.: NCHS, 2001). 8. Henry J. Kaiser Family Foundation, Prescription Drug : A Chartbook (Menlo Park, Calif.: Kaiser Family Foundation, July 2000). 9. Cherry et al., National Ambulatory Medical Care Survey. 10. T.J. Wang et al., Randomized Clinical Trials and Recent Patterns in the Use of Statins, American Heart Journal 141, no. 6 (2001): Kaiser Family Foundation, Prescription Drug. 12. T.W. Croghan, The Controversy of Increased Spending for Antidepressants, Affairs (Mar/Apr 2001): U.S. Department of and Human Services, Report to the President: Prescription Coverage, Spending, Utilization, and Prices (Washington: DHHS, April 2000). 14. A.S. Adams, S.B. Soumerai, and D. Ross-Degnan, The Case for Making a Medicare Drug Coverage Benefit, Annual Review of Public 22 (2001): J.A. Poisal and L. Murray, Growing Differences between Medicare Beneficiaries with and without Drug Coverage, Affairs (Mar/Apr 2001): C.R. Nelson and D.A. Knapp, in Antihypertensive Drug Therapy of Ambulatory Patients by U.S. Office-Based Physicians, Hypertension 36, no. 4 (2000): Agency for care Research and Quality, Acute Pain Management: Operative or Medical Procedures and Trauma Clinical Practice Guideline, Pub. no (Rockville, Md.: AHRQ, February 1992). 18. S. Findlay and D. Sherman, Prescription Drugs and Mass Media Advertising, NIHCM Foundation Research Brief (Washington: National Institute for Care Management, September 2000). 19. Cherry et al., National Ambulatory Medical Care Survey. 20. Kaiser, Prescription Drug. 214 July/August 2002 Downloaded from Affairs.org on April 18, Copyright Project HOPE The People-to-People Foundation, Inc. For personal use only. All rights reserved. Reuse permissions at Affairs.org.
Cost of Mental Health Care
Section 4 Cost of Mental Health Care Per capita mental health spending for Americans with a mental health diagnosis has increased among children, peaking in. For adults, the spending has been more stable.
More informationRe: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments
VIA Electronic Submission to http://www.regulations.gov September 29, 2009 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket
More informationMental health planners and policymakers routinely rely on utilization
DataWatch Measuring Outpatient Mental Health Care In The United States by Mark Olfson and Harold Alan Pincus Abstract: A standard definition of outpatient mental health care does not now exist. Data from
More informationDirect costs of allergic rhinitis in the United States: Estimates from the 1996 Medical Expenditure Panel Survey
Direct costs of allergic rhinitis in the United States: Estimates from the 1996 Medical Expenditure Panel Survey Background: Previous estimates of the cost of allergic rhinitis predate the substantial
More informationPrescription drug expenditures are the most rapidly growing component
Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid Kenneth S. Fink, MD, MGA, MPH 1 Patricia J. Byrns, MD 2 1 Department of Family Medicine, University of North Carolina
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationPrevalence of Mental Illness
Section 1 Prevalence of Mental Illness The prevalence of mental health problems or mental illness appears to be quite stable over time. Full epidemiological surveys of prevalence, reported using complex
More informationManaged Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More informationNational Ambulatory Medical Care Survey: 1995 Summary
Number 286 + May 8, 1997 From Vital and Health Statistics of the CENTERS FOR DISEASE CONTROL AND PREVENTION/National Center for Health Statistics National Ambulatory Medical Care Survey: 1995 Summary by
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationMedicaid Cost Containment and Potential Effects on Diabetic Beneficiaries
Medicaid Cost Containment and Potential Effects on Diabetic Beneficiaries White Paper October 2003 2003 The Health Strategies Consultancy LLC and Duke University, The Fuqua School of Business For more
More informationValue of Hospice Benefit to Medicaid Programs
One Pennsylvania Plaza, 38 th Floor New York, NY 10119 Tel 212-279-7166 Fax 212-629-5657 www.milliman.com Value of Hospice Benefit May 2, 2003 Milliman USA, Inc. New York, NY Kate Fitch, RN, MEd, MA Bruce
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationAssociation of Body Mass Index and Prescription Drug Use in Children from the Medical Expenditures Panel Survey,
Association of Body Mass Index and Prescription Drug Use in Children from the Medical Expenditures Panel Survey, 2003-2006 Yvonne Lin MCH Research Festival June 10, 2009 BMI Changes with Age in Children
More informationInsights Into Physician Behavior AMM Meeting February 12, MARS Medical Med/Surg Readership Study December 2008
Insights Into Physician Behavior AMM Meeting February 12, 29 MARS Medical Med/Surg Readership Study December 28 Three-Part Presentation Important sources of medical information for physician specialties
More informationStudy Exposures, Outcomes:
GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationWide variations in both spending
Hospital Quality And Intensity Of Spending: Is There An Association? Hospitals performance on quality of care is not associated with the intensity of their spending. by Laura Yasaitis, Elliott S. Fisher,
More informationPrescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service
Prescription Drugs Medicare & Medicaid Briefings National Health Policy Forum February 22, 2007 Jim Hahn Congressional Research Service Global and US. Prescription Drug Sales, 1998-2005 $700 $600 559 602
More informationPCMH 2018 Enrollment and Update August 25, 2017
PCMH 2018 Enrollment and Update August 25, 2017 Enrollment Requirements Anne Santifer HealthCare Innovations Department of Human Services 2018 Enrollment Requirements A physician practice that is enrolled
More informationAchieving Quality and Value in Chronic Care Management
The Burden of Chronic Disease One of the greatest burdens on the US healthcare system is the rapidly growing rate of chronic disease. These statistics illustrate the scope of the problem: Nearly half of
More informationSuccesses in Regional Collaboration to Achieve the Triple Aim Oregon. Pay for Performance Summit San Francisco March 24, 2014
Successes in Regional Collaboration to Achieve the Triple Aim Oregon Pay for Performance Summit San Francisco March 24, 2014 Agenda Oregon Health Care Quality Corporation (Q Corp) Background Priority Projects
More informationMarket Distortions from the 340B Drug Pricing Program
Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect
More informationHave you been paying for your prescription drugs? Stop!
Dear Valued Medtipster Member: Have you been paying for your prescription drugs? Stop! Free prescription drugs are NOW just a Medtipster ID card away. Follow the steps below to obtain thousands of generic
More informationMe n t a l h e a l t h a n d substance
Spending For Mental Health And Substance Abuse Treatment, 1996 The first comprehensive look at nationwide spending trends in this decade. b y Da v i d M c Kus i c k, T a m i L. M a r k, E d w ar d K i
More informationMail Order Is Not For Everyone!
Mail Order Is Not For Everyone! Face to face patient counseling by pharmacists can have a powerful impact on long term health care costs and quality. So, the way health plan sponsors promote mail and generics
More informationLike others here today, we are very conflicted on the FDA s proposal on behind-thecounter medications, but thank you for raising the issue.
Statement of Consumers Union William Vaughan, Senior Policy Analyst before the US Food and Drug Administration Public Meeting on Behind the Counter Availability of Drugs November 14, 2007 Consumers Union
More informationRealized Savings from Generic Drugs in Upstate New York
T H E F A C T S A B O U T Realized Savings from Generic Drugs in Upstate New York More Than $130 Million Saved in 2006 Compared With 2005 Finger Lakes Region Estimated generic savings: $29 million Generic
More informationAppendix C CHANGING THE TRAJECTORY:
Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario
More information61 Recommendations for better use of medications
Chapter 61 Recommendations for better use of medications As stated elsewhere in this book, we are fortunate to have a number of effective medications for treatment of many medical conditions. The drug
More informationBilling & Coding Guide
Billing & Coding Guide CMS established a unique J-code to facilitate reimbursement of ENVARSUS XR J7503 Suggested Coding and Medicare Allowables Coding Overview and Payment Rates Used to Report Code Description
More informationUnmanaged Behavioral Health Puts Your Company At Risk. Presented by: Dr. Sam Mayhugh Integrated Behavioral Health
Unmanaged Behavioral Health Puts Your Company At Risk Presented by: Dr. Sam Mayhugh Integrated Behavioral Health Behavioral Health Management Webinar Overview History of BH management Prevalence of behavioral
More informationMedicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment
American Hospital association December 2012 TrendWatch Are Medicare Patients Getting Sicker? Today, Medicare covers more than 48 million people, and that number is growing rapidly baby boomers are reaching
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationSupplementary Online Content
Supplementary Online Content Song Z, Ayanian JZ, Wallace J, He Y, Gibson TB, Chernew ME. Unintended consequences of eliminating Medicare payments for consultations. JAMA Intern Med. Published online November
More informationUpdate to HMO Drug Formulary Tier Definitions. February 8, 2018
Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works
More informationEmergency Department use for Dental Conditions: Trends over 10 years
Emergency Department use for Dental Conditions: Trends over 10 years Introduction More than a decade ago, the Surgeon General s report on Oral health highlighted the importance of oral health, and the
More informationExploring the Relationship Between Substance Abuse and Dependence Disorders and Discharge Status: Results and Implications
MWSUG 2017 - Paper DG02 Exploring the Relationship Between Substance Abuse and Dependence Disorders and Discharge Status: Results and Implications ABSTRACT Deanna Naomi Schreiber-Gregory, Henry M Jackson
More informationAre hypertensive elderly patients treated differently?
ORIGINAL RESEARCH Are hypertensive elderly patients treated differently? Amy DG Huebschmann 1 Caroline Bublitz 2 Robert J Anderson 1 1 University of Colorado-Denver Health Sciences Center (UCDHSC), Department
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 345 A UGUST 16, 2001 NUMBER 7 CHARACTERISTICS OF PATIENTS WITH UNCONTROLLED IN THE UNITED STATES DAVID J.
More informationNational Ambulatory Medical Care Survey: 1997 Summary
Number 305 + May 20, 1999 From Vital and Health Statistics of the CENTERS FOR DISEASE CONTROL AND PREVENTION/National Center for Health Statistics National Ambulatory Medical Care Survey: 1997 Summary
More informationNational Ambulatory Medical Care Survey: 2010 Summary Tables
National Ambulatory Medical Care Survey: 2010 Summary Tables Page 1 National Ambulatory Medical Care Survey: 2010 Summary Tables The Ambulatory and Hospital Care Statistics Branch is pleased to release
More informationHIV/AIDS Care: The Service (CPT) Code Evaluation and Management Series 1
HIV/AIDS Care: The Service (CPT) Code Evaluation and Management Series 1 Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer Learning Outcomes Explain the importance
More informationDr. Sandeep Bhattacharya, Chief Innovation & Strategy Officer, Merck & Co., Inc. / MSD Asia Pacific
Dr. Sandeep Bhattacharya, Chief Innovation & Strategy Officer, Merck & Co., Inc. / MSD Asia Pacific Disclaimer: The opinions expressed in this presentation are the personal opinions of the speaker & do
More informationIntroduction to NHANES and NAMCS
Introduction to NHANES and NAMCS CMU Summer Institute 2002 NHANES: National Health and Nutrition Examination Survey Home Page: http://www.cdc.gov/nchs/nhanes.htm Goal: To provide national estimates of
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.
Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on the Budget Hearing on: 2:00 p.m. 210 Cannon House Office Building National Association of Chain
More informationPrescription Switching and Reduced LDL-C Goal Attainment
Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing
More informationPREVENTION FOR A HEALTHIER AMERICA: Investments in Disease Prevention Yield Significant Savings, Stronger Communities
PREVENTION FOR A HEALTHIER AMERICA: Investments in Disease Prevention Yield Significant Savings, Stronger Communities Jeffrey Levi, PhD Executive Director, Trust for America s Health Barbara A. Ormond,
More informationQUALITY IMPROVEMENT Section 9
Quality Improvement Program The Plan s Quality Improvement Program serves to improve the health of its members through emphasis on health maintenance, education, diagnostic testing and treatment. The Quality
More informationPrescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director
Prescription Drugs North Carolina Policies Carol Steckel, MPH Medicaid Director March 19, 2013 Pharmacy Services Optional service provided each year to about 1.5 million beneficiaries by 2,200 pharmacy
More informationHealth Care Expenditures for Adults With Multiple Treated Chronic Conditions: Estimates From the Medical Expenditure Panel Survey, 2009
Page 1 of 8 SPECIAL TOPIC Volume 10 April 25, 2013 Health Care Expenditures for Adults With Multiple Treated Chronic Conditions: Estimates From the Medical Expenditure Panel Survey, 2009 Steven R. Machlin,
More informationApril 2o14. The 2013 Drug Trend Report Highlights
April 2o14 The 2013 Drug Trend Report Highlights Express Scripts Reports Lowest Specialty Drug Trend Since 2007 In 2013, spending on prescription drugs increased 5.4% after several years of slower-paced
More informationDrug Coverage for EpiPens to Change July 1
Drug Coverage for EpiPens to Change July 1 Epinephrine auto-injector pens (e.g., EpiPen and Adrenaclick ) have seen recent cost increases, now with a price tag of more than $600 for each prescription.
More informationDisease Management. Measures At A Glance
s At A Glance Updated: 11/01/2018 URAC 2018 Page 1 of 7 Cross-Cutting Mandatory s (3) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on
More informationCFO Council. Physician Compensation Trends. Survey Challenges
CFO Council Physician Compensation Trends 1 Survey Challenges Many healthcare organizations use surveys in their compensation plans. Some to set specific targets and benchmarks and others to determine
More informationLIPITOR AND YOU HELPFUL INFORMATION FOR UNDERSTANDING CHOLESTEROL AND RISKS
LIPITOR AND YOU HELPFUL INFORMATION FOR UNDERSTANDING CHOLESTEROL AND RISKS Learn what your cholesterol levels actually mean, and how you may save money on your prescription each month with the LIPITOR
More informationFrequency Estimates from Prescription Drug Datasets. (Revision of # A)
Frequency Estimates from Prescription Drug Datasets (Revision of #04-11-066A) Swu-Jane Lin, Ph.D. 1 1, 2, 3 Bruce Lambert, Ph.D. Hiangkiat Tan, B. Pharm, M.S. 1 Sengwee Toh, B. Pharm. 1 1 Department of
More informationArkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual
Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual 2017 This document is a guide to the 2017 Arkansas Blue Cross and Blue Shield Patient-Centered Medical
More informationImpact of New Antihypertensives on Healthcare Utilization by Hypertensive Patients
At a Glance Pharmacoeconomics Practical Implications p 139 Author Information p 144 Full text and PDF www.ajpblive.com Impact of New Antihypertensives on Healthcare Utilization by Hypertensive Patients
More informationRacial Variation In Quality Of Care Among Medicare+Choice Enrollees
Racial Variation In Quality Of Care Among Medicare+Choice Enrollees Black/white patterns of racial disparities in health care do not necessarily apply to Asians, Hispanics, and Native Americans. by Beth
More information2018 Edition The Current Landscape of Genetic Testing
2018 Edition The Current Landscape of Genetic Testing Market growth, reimbursement trends, challenges and opportunities November April 20182017 EXECUTIVE SUMMARY Concert Genetics is a software and managed
More informationOCHSNER PHYSICIAN PARTNERS. PQRS Measures by Specialty (FINAL)
OCHSNER PHYSICIAN PARTNERS PQRS Measures by Specialty (FINAL) Allergy and Immunology 2. Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting (PQRS 53) 3. Patients aged 18 years
More informationTrends in Emergency Department Visits for Ischemic Stroke and Transient Ischemic Attack: United States,
Trends in Emergency Department Visits for Ischemic Stroke and Transient Ischemic Attack: United States, 2001 2011 Anjali Talwalkar, M.D., M.P.H.; and Sayeedha Uddin, M.D., M.P.H. Key findings Data from
More informationTips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015
Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead
More informationMETHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC
PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM S.P. Lee 1 ; K. Lang 2 ; J. Jackel 2 ;
More informationThe national Health Expenditure
Health Tracking Trends National Health Spending By Medical Condition, 00 Mental disorders and heart conditions were found to be the most costly. by Charles Roehrig, George Miller, Craig Lake, and Jenny
More informationAge of Drinking Onset, Driving After Drinking, and Involvement in Alcohol Related Motor Vehicle Crashes
Title: Age of Drinking Onset, Driving After Drinking, and Involvement in Alcohol Related Motor Vehicle Crashes Author(s): Affiliation: Hingson, R., Heeren, T., Levenson, S., Jamanka, A., Voas, R. Boston
More informationTRENDS IN PNEUMONIA AND INFLUENZA MORBIDITY AND MORTALITY
TRENDS IN PNEUMONIA AND INFLUENZA MORBIDITY AND MORTALITY AMERICAN LUNG ASSOCIATION RESEARCH AND PROGRAM SERVICES EPIDEMIOLOGY AND STATISTICS UNIT February 2006 TABLE OF CONTENTS Trends in Pneumonia and
More informationSPECIAL ISSUE. Medicaid Prescription Drug Access Restrictions: Exploring the Effect on Patient Persistence With Hypertension Medications
Medicaid Prescription Drug Access Restrictions: Exploring the Effect on Patient Persistence With Hypertension Medications Jerome Wilson, PhD; Kirsten Axelsen, MS; and Simon Tang, MPH Objective: To compare
More informationPharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationUnited States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America
United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America September 26, 2017 USND Report Background This report is the culmination of research to identify and better
More information2017 Drug Trend Report Commercial Medicare Medicaid Exchanges
2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Finance Committee Hearing on: 10:30 a.m. 215 Dirksen Senate Office Building National Association of Chain Drug Stores (NACDS)
More informationChristopher Okunseri, BDS, MSc, MLS, DDPHRCSE, FFDRCSI, Elaye Okunseri, MBA, MSHR, Thorpe JM, PhD., Xiang Qun, MS.
Dental Health Services Research Team Christopher Okunseri, BDS, MSc, MLS, DDPHRCSE, FFDRCSI, Elaye Okunseri, MBA, MSHR, Thorpe JM, PhD., Xiang Qun, MS., Aniko Szabo, PhD Research Support: National Institute
More informationUsing Big Data to Empower Consumer Choice. Oregon State of Reform Health Policy Conference September 24, 2014
Using Big Data to Empower Consumer Choice Oregon State of Reform Health Policy Conference September 24, 2014 Agenda Big data Ideal state for consumers The best and worst of health information What is coming
More informationMEASURING CARE QUALITY
MEASURING CARE QUALITY Region December 2013 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
More informationUltrasound Reimbursement Guide 2015: BioJet Fusion
Ultrasound Reimbursement Guide 2015: BioJet Fusion Diagnosis codes explain the rationale for a given service and are a key factor in a payer s evaluation of medical necessity and coverage determination
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More information5. Current Activities
5. Current Activities 5. Current Activities The following discussion suggests only some of the kinds of activities and resources that can contribute to postmarketing surveillance. The Food and Drug Administration
More informationDrug Guide. April New Specialty Drug Approvals. New Formulations for Existing Drugs
April 2013 The MedTrak Drug Guide provides a monthly update on recent approvals by the Food and Drug Administration (FDA). Use the chart below as a valuable reference tool. Additional detailed information
More informationKey Findings. Mortality Rates
Mortality Rates Statewide in-hospital mortality rates showed a statistically significant decrease from to in nine of the 15 conditions reported. The largest decrease was in, where the mortality rate decreased
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationMedication Therapy Management Solution
Medication Therapy Management Solution A Medicaid Case Report It s often challenging to include evidencebased clinical programs that offer financial benefits. However, pharmacotherapy is central to the
More informationGeneric-brand Comparison Handbook 2010
Generic-brand Comparison Handbook 2010 The chart below provides a comparison of medications that are commonly used to treat (Information pertains to U.S. products). Generic. (Brand). Usual Dose 2012),
More informationDisease Management. Measures At A Glance
s At A Glance Updated: 11/2/2017 Page 1 of 7 Cross Cutting Mandatory s (4) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual
More informationMultiple Chronic Conditions: A New Paradigm for Approaching Chronic Disease
Multiple Chronic Conditions: A New Paradigm for Approaching Chronic Disease American Medical Group Association October 26, 2012 Richard A. Goodman, MD Office of the Assistant Secretary for Health U.S.
More informationAdverse drug events in the outpatient setting: an 11-year national analysis
Adverse drug events in the outpatient setting: an 11-year national analysis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation
More informationCommon Diagnosis Codes and Tips for Coding Nicotine Use/
ICD-10 Tobacco Billing Guide ICD-10 and Tobacco Common Diagnosis Codes and Tips for Coding Nicotine Use/ Dependence Tobacco use is the leading cause of preventable disease and death in the United States,
More informationTexas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018
Texas Vendor Drug Program Formulary Drug Index File Layout Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 The Vendor Drug Program provides a weekly update of resource data available for download
More informationExecutive Summary. Classes Under Review: Analysis:
Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation
More informationANN M. HAMER, PharmD, BCPP; DANIEL M. HARTUNG, PharmD; DEAN G. HAXBY, PharmD; KATHY L. KETCHUM, RPh, MPA:HA; and DAVID A.
RESEARCH Initial Results of the Use of Prescription Order Change Forms to Achieve Dose Form Optimization (Consolidation and Tablet Splitting) of SSRI Antidepressants in a State Medicaid Program ANN M.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Caduet) Reference Number: CP.CPA.237 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationIssues for Part D Compliance
HCCA- MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE Issues for Part D Compliance Craig Miner, RPh, JD Division of Drug Plan Policy Babette S. Edgar, Pharm.D., MBA Division of Finance and Operations
More informationThe standard Medicare Part D drug coverage is divided into 3
Assessment of Drug Consumption Patterns for Medicare Part D Patients Alex Pedan, PhD; Jingsong Lu, MS; and Laleh T. Varasteh, RPh, MSF The standard Medicare Part D drug coverage is divided into 3 consecutive
More informationAbout the PCTB Examination Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p.
Preface p. ix About the PCTB Examination p. xii Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p. 4 The Retail Medication Order p. 6
More informationTEXAS MANAGED CARE DIGEST SERIES TYPE 2 DIABETES REPORT. Texas Business Group on Health TBGH
2010 Business Group on Health TBGH TEXAS TYPE 2 DIABETES REPORT SPECIAL FEATURE: MSA comparisons Featuring Demographic, Utilization, Pharmacotherapy and Charge Data Business Group on Health MANAGED CARE
More informationOutpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years
Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years 2004-2008 Laura Governale, Pharm.D., MBA Team Leader, Drug Utilization Data Analyst Hina Mehta, Pharm.D. Drug Utilization
More information